Sign In
Buy OYST
$11.17
+0 (+0%)
At Close: Mar 29, 2023
Citigroup Inc. Buys 519 Shares of Oyster Point Pharma (NASDAQ:OYST)
05:32am, Wednesday, 24'th Jun 2020
Citigroup Inc. increased its stake in shares of Oyster Point Pharma (NASDAQ:OYST) by 46.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchan
6 Stocks That Could Slide
12:00am, Thursday, 18'th Jun 2020
Stocks Analysis by Harry Boxer covering: FLIR Systems Inc, eHealth Inc, Haemonetics Corporation, Royal Caribbean Cruises Ltd. Read Harry Boxer's latest article on Investing.com
Pandemic brings a rising tide of Bay Area boat sales
11:00am, Friday, 05'th Jun 2020
With double-digit unemployment and shelter-in-place restrictions, Bay Area yacht broker Geli Burgin was certain 2020 would be a bad summer for the boat business. She was wrong.
Is Oyster Point Pharma, Inc. (OYST) A Good Stock To Buy?
03:39pm, Monday, 01'st Jun 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
How Oyster Point (OYST) Stock Stands Out in a Strong Industry
01:07pm, Thursday, 28'th May 2020
Oyster Point (OYST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
3 Top Pharma Stocks to Buy Right Now
04:25pm, Sunday, 24'th May 2020
Healthcare investors can look past the development risk. Global Blood Therapeutics (NASDAQ: GBT) crushed analyst estimates when it reported its first-quarter results on May 6. In its first full quar
Zelensky appoints Georgian, who built Batumi, to head investment office: Who is Levan Varshalomidze?
12:00am, Thursday, 21'st May 2020
President Volodymyr Zelensky promised to open an investment office under the leadership of Levan Varshalomidze, ex-head of the Adjara government
PRINCETON, N.J., May 19, 2020 -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of.
Oyster Point Pharma Announces Pricing of an Upsized Offering of Common Stock
06:02am, Friday, 15'th May 2020
PRINCETON, N.J., May 15, 2020 -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of.
The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
12:00am, Friday, 15'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 14)
Allogene Therapeutics Inc (...
S-1: Oyster Point Pharma, Inc.
03:39am, Wednesday, 13'th May 2020
(EDGAR Online via COMTEX) --
Table of Contents As filed with the Securities and Exchange Commission on May 12, 2020. Registration No. 333- UNITED STATES...
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
12:00am, Wednesday, 13'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
Oyster Point Pharma Proposed Public Offering of Common Stock
08:20pm, Tuesday, 12'th May 2020
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface dis
Protalix Fabry Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
06:09pm, Tuesday, 12'th May 2020
Protalix reported positive data from its Fabry disease trial. AtriCure reported positive data from its CONVERGE Study. Oyster Point Pharma reported mixed toplin
Oyster Point Pharma, Inc. (OYST) Q1 2020 Earnings Call Transcript
02:31am, Tuesday, 12'th May 2020
Good morning, everyone, and welcome to the Oyster Point conference call to discuss top-line results for the Phase 3 ONSET-2 clinical trial in patients with dry eye disease. This morning, we issued tw
